ADMIN 
A randomized trial involving 1,000 adults with septic shock found that restricting additional intravenous fluids and starting vasopressors earlier did not increase days alive and out of hospital by day 90, compared with a strategy using more fluids and later vasopressors.
The ARISE FLUIDS trial, conducted in emergency departments in Australia, New Zealand and Ireland, was published in the New England Journal of Medicine in June 2026. The result addresses two early treatment strategies for selected adults presenting with septic shock. It is not a prescription for every patient.
What the researchers compared
Investigators randomly assigned patients to one of two approaches for at least six hours and up to 24 hours. The vasopressor group received restricted fluid volumes and earlier vasopressor treatment. The fluids group received higher fluid volumes, with vasopressors introduced later. Both groups received medical care for septic shock; this was not a trial of treatment versus no treatment.
Researchers enrolled 1,000 people, with 499 assigned to the vasopressor group and 501 to the fluids group. The primary outcome was days alive and out of hospital from randomization through day 90. Patients who died during that period contributed no days to this measure.
The main result was the same median in both groups
At day 90, the median number of days alive and out of hospital was 76 in each group. The reported difference was 0.0 days, with a 95% confidence interval from minus 2.7 to 2.7 days and a P value of 1.00. The trial did not find a recovery advantage on its primary outcome for early vasopressors.
The treatment groups received meaningfully different amounts of fluid. In the first 24 hours, the vasopressor group received a median 1,108 milliliters less intravenous fluid. Vasopressor use was 18.9 percentage points higher in that group. These differences show that the trial compared distinct approaches even though the primary patient-centered outcome was similar.
Pulmonary edema occurred in 0.6% of the vasopressor group and 5.0% of the fluids group. That is a notable secondary finding, but it should not be turned into a claim that early vasopressors improve overall survival or are automatically safer for every patient.
What the trial does not prove
The findings apply to the patients and settings enrolled. They do not establish that one strategy is optimal for all forms or stages of sepsis, for patients with different medical histories, or in every hospital. The trial was open-label, meaning clinicians knew which strategy was being used.
The result does not mean clinicians should delay fluids or start vasopressors without assessment. Septic shock is a medical emergency. Decisions about resuscitation require trained clinicians to consider blood pressure, perfusion, fluid responsiveness, heart and kidney function, infection source and ongoing response.
Why the study matters
Treatment must balance restoring circulation against the risks of excess fluid. This trial adds randomized evidence from emergency departments in three countries. It found no advantage on the 90-day recovery measure for a restricted-fluid, earlier-vasopressor strategy, while fluid exposure was lower and observed pulmonary edema was less common in that group.
Questions remain about different patient subgroups and longer-term outcomes. The published trial should be read alongside other sepsis research and future guideline updates, not as a stand-alone prescription.
Frequently asked questions
Did early vasopressors save more lives?
The primary outcome—days alive and out of hospital by day 90—was not better in the early-vasopressor group. The study did not establish a survival advantage.
Were fluids stopped?
No. The trial compared restricted fluid volumes with earlier vasopressors against higher fluid volumes with later vasopressors.
Does this change what a patient should do?
No. This is clinical research, not individual medical advice. Anyone who may have sepsis needs urgent professional assessment.
Sources: NEJM trial; ClinicalTrials.gov record
